GlassScriptPhysician profile
James W Chu
NPI 1710969266
$638,968.90
in general payments reported to CMS, 2019-2025
41 companies · $64K in 2025
The $64K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $111K · 2021: $95K · 2022: $87K · 2023: $68K · 2024: $89K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $190K · Travel and Lodging: $21K · Food and Beverage: $10K · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $189,925.00 |
| Travel and Lodging | $20,527.47 |
| Food and Beverage | $10,103.04 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $497,050.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82,357.67 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $32,787.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $21,311.70 | 2019-2023 | Farxiga |
| Abbott Laboratories | $827.80 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $557.02 | 2019-2025 | Evenity, Prolia, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $410.11 | 2022-2025 | |
| Dexcom, INC. | $374.76 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $363.88 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $329.31 | 2019-2024 | Afrezza |
| Radius Health, INC. | $318.79 | 2019-2025 | Tymlos |
| Abbvie INC. | $261.67 | 2019-2025 | |
| Novo Nordisk INC | $233.57 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $178.54 | 2019-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $157.27 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $129.19 | 2019-2024 | Strensiq |
| Merck Sharp & Dohme LLC | $122.61 | 2019-2020 | |
| Kyowa Kirin, INC. | $114.87 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $102.75 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $99.79 | 2025 | Rezdiffra |
| Medtronic, INC. | $84.74 | 2022-2023 | Minimed 780g, Minimed 770g |
| Eli Lilly and Company | $74.63 | 2019-2021 | |
| Beta Bionics, INC. | $72.22 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascensia Diabetes Care US INC. | $68.56 | 2024 | |
| Cequr Corporation | $63.12 | 2023 | Cequr Simplicity |
| Shire North American Group INC | $60.67 | 2019 | |
| Insulet Corporation | $58.70 | 2019-2025 | Omnipod |
| Horizon Therapeutics Plc | $58.44 | 2019-2023 | Tepezza |
| Tandem Diabetes Care, INC. | $57.92 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Eli Lilly Export S.A. Puerto Rico Branch | $43.05 | 2020 | |
| Boston Scientific Corporation | $38.73 | 2025 | General - Pain Management |
| Regeneron Healthcare Solutions, INC. | $37.99 | 2025 | Evkeeza |
| Soleno Therapeutics, INC. | $26.75 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $25.23 | 2025 | Twiist |
| Medtronic Minimed, INC. | $21.79 | 2019 | |
| Amarin Pharma, INC. | $21.74 | 2020 | |
| Amryt Pharma Holdings LTD | $20.14 | 2023 | Mycapssa |
| Kowa Pharmaceuticals America, INC. | $16.24 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.88 | 2019 | |
| Tolmar, INC. | $13.22 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,030.37 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.